FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

 FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

FDA approves IV Poteligeo for Treating Two Rare types of Cutaneous T cell lymphoma (CTCL)

Shots:

  • FDA approves Kyowa Kirin’s Poteligeo drug for R/R Mycosis fungoides (MF) and Sézary syndrome (SS)
  • Poteligeo received Orphan Drug designation with addition permission granted on basis of Priority Review and Breakthrough Therapy
  • The approval is based on a clinical trial of 372 patients with MF or SS. Study reported mPFS (Poteligeo vs Vorinostat) is 7.6mos vs 3.1mos
Click here to read full press release/ article | Ref: US FDA | Image: BioNJ 

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post